MTSR
Price:
$70.5
Market Cap:
$7.43B
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New York.
Industry
Biotechnology
IPO Date
2025-01-31
Stock Exchange
NASDAQ
Ticker
MTSR
According to Metsera, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -23.58. This represents a change of 123.52% compared to the average of -10.55 of the last 4 quarters.
The mean historical PE Ratio of Metsera, Inc. over the last ten years is -556.44. The current -23.58 PE Ratio has changed 323.77% with respect to the historical average. Over the past ten years (40 quarters), MTSR's PE Ratio was at its highest in in the September 2024 quarter at -4.68. The PE Ratio was at its lowest in in the December 2023 quarter at -27.87.
Average
-556.44
Median
-28.04
Minimum
-1627.96
Maximum
-13.31
Discovering the peaks and valleys of Metsera, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual PE Ratio = -13.31
Minimum Annual Increase = -98.28%
Minimum Annual PE Ratio = -1627.96
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | -13.31 | -52.52% |
| 2023 | -28.04 | -98.28% |
The current PE Ratio of Metsera, Inc. (MTSR) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-556.44
5-year avg
-556.44
10-year avg
-556.44
Metsera, Inc.’s PE Ratio is less than Nuvalent, Inc. (-20.21), greater than Axsome Therapeutics, Inc. (-32.26), less than Merus N.V. (-20.81), less than CRISPR Therapeutics AG (-10.83), less than Cytokinetics, Incorporated (-10.62), less than Vaxcyte, Inc. (-9.55), greater than Rhythm Pharmaceuticals, Inc. (-35.36), greater than Abivax S.A. (-30.21), greater than Arrowhead Pharmaceuticals, Inc. (-60.57), less than Arcellx, Inc. (-20.47),
| Company | PE Ratio | Market cap |
|---|---|---|
| -20.21 | $7.77B | |
| -32.26 | $7.46B | |
| -20.81 | $7.30B | |
| -10.83 | $5.09B | |
| -10.62 | $7.92B | |
| -9.55 | $6.03B | |
| -35.36 | $7.05B | |
| -30.21 | $8.36B | |
| -60.57 | $8.94B | |
| -20.47 | $3.79B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Metsera, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Metsera, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Metsera, Inc.'s PE Ratio?
How is the PE Ratio calculated for Metsera, Inc. (MTSR)?
What is the highest PE Ratio for Metsera, Inc. (MTSR)?
What is the 3-year average PE Ratio for Metsera, Inc. (MTSR)?
What is the 5-year average PE Ratio for Metsera, Inc. (MTSR)?
How does the current PE Ratio for Metsera, Inc. (MTSR) compare to its historical average?